Optimized background regimen

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with[...]

By afschroeder • June 5, 2025